Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Atrium Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Atrium Therapeutics, Inc.’s stock price such as:

• Atrium Therapeutics, Inc.’s current stock price and volume
• Why Atrium Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for RNA from analysts
• RNA’s stock price momentum as measured by its relative strength

About Atrium Therapeutics, Inc. (RNA)

Before we jump into Atrium Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

Want to learn more about Atrium Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Atrium Therapeutics, Inc..

Atrium Therapeutics, Inc.’s Stock Price as of Market Close

As of August 07, 2026, 1:59 PM, CST, Atrium Therapeutics, Inc.’s stock price was $12.300.

Atrium Therapeutics, Inc. is up 1.57% from its previous closing price of $12.110.

During the last market session, Atrium Therapeutics, Inc.’s stock traded between $12.145 and $12.480. Currently, there are approximately 17.11 million shares outstanding for Atrium Therapeutics, Inc..

Atrium Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Atrium Therapeutics, Inc. Stock Price History

Atrium Therapeutics, Inc.’s (RNA) price is currently up 8.37% so far this month.

During the month of August, Atrium Therapeutics, Inc.’s stock price has reached a high of $12.480 and a low of $11.300.

Over the last year, Atrium Therapeutics, Inc. has hit prices as high as $16.770 and as low as $11.130. Year to date, Atrium Therapeutics, Inc.’s stock is down 82.95%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Atrium Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 06, 2026, there were analysts who downgraded Atrium Therapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Atrium Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Atrium Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Atrium Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Atrium Therapeutics, Inc. (RNA) by visiting AAII Stock Evaluator.

Relative Price Strength of Atrium Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 06, 2026, Atrium Therapeutics, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Atrium Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Atrium Therapeutics, Inc. Stock Price: Bottom Line

As of August 7, 2026, Atrium Therapeutics, Inc.’s stock price is $12.300, which is up 1.57% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Atrium Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.